Eikonizo Therapeutics, a Cambridge, MA-based biopharmaceutical company dedicated to developing disease-modifying therapies, received an investment from Novo Nordisk through its Science2Medicine iNNvest initiative.
The amount of the deal was not disclosed.
The company intends to use the funds to consolidate the development of its lead candidate, EKZ-102, and enable the advancement of novel HDAC6 inhibitors.
Led by President and CEO Rick Lundberg, Eikonizo is developing novel, disease-modifying small molecule therapeutics targeting histone deacetylase 6 (HDAC6) to improve the lives of people impacted by neurodegenerative and cardiorenal diseases.
Eikonizo’s lead development candidate, EKZ-102, is a first-in-class, oral, small molecule HDAC6 inhibitor with the distinctive combination of high potency, selectivity and CNS penetrance necessary to protect neuronal function while minimizing potential off-target side effects to achieve a favorable safety and tolerability profile. EKZ-102 is in IND-enabling development for the treatment of ALS with planned expansion to other neurodegenerative disorders.
Eikonizo also announced key additions to strengthen its leadership with the appointment of Thomas E. Hughes, PhD, Chairperson and Chief Executive Officer of Navitor Pharmaceuticals, to its Board of Directors, as well as Richard A. Fisher, PhD, as Chief Scientific Officer, Jim Luterman, PhD, as Executive Vice President of Development and Jon Graves, CPA as Vice President, Finance and Controller.
FinSMEs
11/12/2024